Drug intelligence / Profile preview

RLP068

Development stage: Phase 1
Lead developer: Molteni Farmaceutici
Modality: Small Molecules
Administration: Topical

Overview

RLP068 is a **cationic zinc phthalocyanine derivative** used in **photodynamic therapy (PDT)** for treating superficial bacterial and fungal infections. It works by producing **singlet oxygen** and other reactive oxygen species (ROS) upon activation by red light, leading to a rapid bactericidal and fungicidal effect. RLP068 is particularly effective against drug-resistant pathogens, such as **MRSA**, and is used to treat conditions like diabetic foot ulcers and venous ulcers. It is applied topically and activated with red light.

Brand names: VULNOFAST plus
Other names: RLP068/Cl

Targets

Microbial cell wall and membrane

Beyond the preview

Go deeper on RLP068.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RLP068.